Zacks Research Analysts Raise Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research raised their Q1 2026 EPS estimates for shares of Corcept Therapeutics in a note issued to investors on Monday, January 27th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $0.46 per share for the quarter, up from their previous estimate of $0.45. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.74 EPS, Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $2.50 EPS.

Several other research analysts have also issued reports on CORT. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Finally, StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $65.25.

Corcept Therapeutics Stock Up 1.4 %

CORT stock opened at $61.53 on Wednesday. The firm’s 50-day simple moving average is $55.55 and its 200 day simple moving average is $46.50. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a market cap of $6.45 billion, a PE ratio of 48.83 and a beta of 0.56. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $62.98.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. During the same period last year, the business posted $0.28 earnings per share. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis.

Insider Transactions at Corcept Therapeutics

In related news, insider Joseph Douglas Lyon sold 1,411 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.72, for a total transaction of $80,031.92. Following the completion of the transaction, the insider now owns 8,494 shares in the company, valued at approximately $481,779.68. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $50.54, for a total value of $111,188.00. The disclosure for this sale can be found here. Insiders have sold 38,011 shares of company stock worth $1,951,268 in the last three months. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CORT. Capital Performance Advisors LLP acquired a new stake in shares of Corcept Therapeutics during the 3rd quarter worth about $25,000. Kathleen S. Wright Associates Inc. acquired a new position in Corcept Therapeutics in the 3rd quarter valued at about $36,000. USA Financial Formulas bought a new stake in shares of Corcept Therapeutics during the fourth quarter worth approximately $54,000. Newbridge Financial Services Group Inc. acquired a new position in shares of Corcept Therapeutics in the fourth quarter valued at approximately $58,000. Finally, GAMMA Investing LLC increased its stake in shares of Corcept Therapeutics by 85.4% during the third quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 1,147 shares during the period. 93.61% of the stock is currently owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.